Raadysan Biotech, Inc., is a biotechnology company that is involved in the Research & Development of its highly differentiated therapies for Triple Negative Breast Cancer.
The Company is led by exceptional scientists whose visionary outlook has been instrumental in several innovative discoveries reflected in the Company’s portfolio and highly experienced Clinicians, Advisors and Management team.
The Company has been awarded the “Most Visionary Woman-Owned Biotech Company” for 2024, by Global Health & Pharma News!
Rakhee Gupte, MS, PhD, CEO & President
Dr. Gupte has over 20 years of academic (microbiology, biochemistry, molecular & cell biology & immunology) and pharmaceutical experience and has identified several novel signaling pathways in oncology and cardiovascular diseases that led to the discoveries of unique molecular targets for therapeutic intervention.
Dr. Gupte received her B.S. and M.S. in Microbiology from the University of Bombay. She was employed as Senior Scientific Officer in Neo-Pharma, Bombay, India and gained industrial expertise in quality assurance/control, product management, training medical representatives and liaison with medical fraternity. She has patented a method for expediting the detection of four pathogens in clinical samples in 3 days.
She received her Ph.D. in Biochemistry & Molecular Biology from the New York Medical College, Valhalla, NY, where she also did her post-doctoral fellowship and became Research Associate in the department of Physiology. She was appointed as Assistant Professor at University of South Alabama, Mobile, AL. Currently, she is appointed as a Visiting Scientist in the Department of Pharmacology, New York Medical College, Valhalla, NY. She holds 5 US patents and has published over 20 abstracts and 21 full-length publications in peer-reviewed scientific journals. Over the course of 15 years, Dr. Gupte has received numerous honors and awards for her scholastic achievements. She has supervised and trained numerous students and post-doctoral fellows in lab facilities as well as conducted lectures at New York Medical College and University of South Alabama. Her scientific research highlights Includes identifying signaling pathways in DNA replication, mitosis and cytokinesis in cancer cells and elucidating mechanisms that are instrumental for stalling DNA replication and cytokinesis in adult rat cardiac myocytes.
She is a member of the NewYorkBIO; Women in Bio, NY Metro; Female Founders Alliance; and Women’s Leadership Alliance.
Steven Taylor, BSc, PhD, Chief Scientific Officer
Dr Taylor has 15 years experience in drug discovery and development. He received his bachelor’s degree and PhD in Chemistry from the University of Sheffield, UK and undertook postdoctoral studies in synthetic bioorganic chemistry in the University of Bath, UK. Subsequently, he was employed as a medicinal chemist in a number of start-up to medium sized pharmaceutical and CRO companies including Peptide Therapeutics (latterly spun out to Medivir UK), Rodaris Pharmaceuticals, British Biotech, Evotec, and Midatech Pharma. Dr. Taylor has expertise in all aspects of medicinal chemistry including structure based drug design, HTS screens, and fast follower approaches, GMP manufacture, quality, formulation, analytical chemistry and regulatory development.
Dr Taylor served as the Group Leader, at Evotec, where he was in charge of supervising Evotec’s collaborations with Develogen, on metabolic disorders; and Pharma Division on CNS targets. Dr Taylor then served as VP Chemistry in Midatech Pharma, where his projects concentrated on the GMP manufacture and subsequent development of a first in class novel insulin bound nanoparticle through to a phase 2 clinical trial; and drug discovery activities using the company’s proprietary nanoparticle technology to target chemotherapeutics for the treatment of cancers. Dr Taylor has authored/co-authored 15 patent applications and 9 publications.
Roderike Pohl, PhD, Vice President-Research
Dr. Pohl has over 18 years of pharmaceutical experience in pharmaceutics, bio-pharmaceutics and preclinical research. She received her B.S in Biology and Ph.D. in Pharmaceutics from the University of Connecticut, Storrs, CT. Her scientific research covered topics in diabetes (insulin & glucagon formulations, device development), pulmonary drug delivery, confocal microscopy, scanning electron microscopy, immunology and parasitology.
Dr. Pohl was a co-founder and Vice President of Research at Biodel Inc. (2004-2016). Previously, she worked for Mannkind Corporation as Vice President of Preclinical Research (2001-2003), and Pharmaceutical Discovery Corporation, Elmsford, NY (1998-2001) as Director of Biopharmaceutics and Preclinical Research. Dr. Pohl has authored/co-authored 14 issued US patents, multiple international patents, and has an additional 10 patents pending. She has 15 peer reviewed publications and 59 abstracts presented at domestic and international meetings.
Dr. Pohl is a member of the American Association of Pharmaceutical Scientists (AAPS), European Association for the Study of Diabetes (EASD), Controlled Release Society (CRS), American Diabetes Association (ADA) and American Chemical Society (ACS). She was the recipient of a PhRMA Pre-doctoral Fellowship in Pharmaceutics in 1995.
Linda Vahdat, MD, MBA, Medical Advisor
Dr. Vahdat is board certified in internal medicine and medical oncology. She is the Deputy Cancer Center Director, Chief of the section of Medical Oncology and interim Chief of Hematology at the Dartmouth-Hitchcock’s Norris Cotton Cancer Center (NCCC) In her academic role, she will serve as the Milham Professor and Professor of Medicine at Dartmouth’s Geisel School of Medicine. Previously she was the Chief of Cancer Services and head of the Department of Hematology/Oncology at the Memorial Sloan Kettering Cancer Center Center–Norwalk Hospital Partnership.
Dr. Vahdat earned a medical degree from Mount Sinai Medical School in 1987 and completed a residency in Internal Medicine at Mount Sinai Hospital. She then completed her fellowship in Medical Oncology/Hematology at MSKCC. She later received an MBA from the Massachusetts Institute of Technology in 2014.
She has over 20 years of experience in caring for patients with breast cancer, with a particular focus on triple-negative breast cancer, metastatic breast cancer and breast cancer at high risk of recurring. Her expertise extends to drug development. She has been involved in the identification, conceptualization, design and conduct of Phase 0 through III clinical trials of new therapies in high-risk adjuvant and metastatic breast cancer patients since 1994. She has led three separate drug-development efforts that led to FDA approval of three drugs active in metastatic breast cancer. She founded the Triple Negative Breast Cancer Clinic, the second in the U.S., in 2014.
She has been recognized as one of America’s Top Doctors for cancer from 2016 to 2020, included in the Castle Connolly: New York Magazine Top Doctors (2017-2020) and Top Doctors New York Metro Area (2016-2020). Dr. Vahdat has also been actively involved with—and has held several leadership positions in—the American Society of Clinical Oncology, including co-chair of the ASCO Breast Cancer Symposium, and served on the Executive Board of Cancer Care from 2006 until 2012.
Elizabeth Phillips, MD, FACP, Medical Advisor
Dr. Phillips is a board-certified Hematologist and Medical Oncologist. She is an attending physician at Montefiore Medical Center and practices in New Rochelle, NY, with a focus on breast cancer.
Dr. Phillips is a graduate of Stanford University, and received her MD from the University of Washington. She did her residencies in Internal Medicine at Harlem Hospital Center (NYC) and in Hematology at Montefiore Medical Center and completed fellowships in Leukemia and Medical Oncology at Memorial Sloan Kettering Cancer Center.
After serving as a full-time faculty member at Long Island Jewish Medical Center, Dr. Phillips joined an Oncology practice at Montefiore Medical Center, in New Rochelle, where she was involved in a number of clinical trials.
Dr. Phillips has been in practice for more than 20 years, and has been voted as one of the “Top Doctors” in her field in Westchester County for more than ten years. She is also a Clinical Associate Professor of Medicine at New York Medical College.
Nicholas Landekic, MA, MBA, Corporate Development Advisor
Mr. Landekic has over 30 years of small biotech and big pharma experience in corporate development, marketing, finance, and development of novel therapeutic drugs. He received his MBA in Finance/Marketing from State University of New York at Albany, and his MA in Biology from Indiana University. He was a Research Scientist in Environmental Medicine at Mount Sinai Medical Center, New York, New York.
His is a serial entrepreneur and founder of Karunix, Inc., and PolyMedix, Inc. He has extensive expertise in Product development, marketing, and repositioning to maximize commercial returns, e.g. includes Provigil/modafinil, Gliadel, and Stadol NS. He has worked on 26 pre-clinical research programs, 16 clinical programs, and 7 successful marketed drugs in oncology, neurology, bacterial and viral infectious diseases, respiratory disorders. He successfully secured $400 million in 25 public and private financings.
Prior to been an entrepreneur, Mr. Landekic served as the President & Chief Executive Officer, Director, at Locus Discovery Inc., Blue Bell, Pennsylvania, and earned for the company the accolade “One of the 10 hottest biotechnology start-ups” by Drug Discovery Today magazine, Feb. 2002. His other prior appointments include Senior Vice President, Corporate Development and Communications, Guilford Pharmaceuticals, Baltimore, Maryland; Senior Director, Business Development, Cephalon, Inc., West Chester, Pennsylvania; Senior Manager, Strategic Marketing & Product Planning, Bristol-Myers Squibb Corporation, Princeton, New Jersey; Manager, New Business Development; Johnson & Johnson Corporation, McNeil Pharmaceutical, Spring House, PA.
He earned the “Investor’s Choice” Award at the 2002 Lifescience Venturewire conference and was Nominated by Allicense/Recombinant Capital as candidate for “1997 Deal of the Year”.
Paul Mieyal, PhD, CFA, Strategic Advisor
Dr. Mieyal has over 15 years of experience in healthcare investments. He received his Ph.D. in pharmacology from New York Medical College, a B.A. in chemistry and psychology from Case Western Reserve University, and is a Chartered Financial Analyst.
He is the Vice President and Director of Life Sciences Investments of Wexford Capital LP, an SEC registered investment advisor based in Greenwich, CT with $3 billion of assets under management. Prior to that, he was Vice President in charge of health care investments for Wechsler & Co., Inc. a private investment firm and registered broker dealer. Dr. Mieyal serves as director of Nephros (NEPH), and several private companies, including Optiscan Biomedical, Interventional Spine, ElMindA, and Microbiogen Pty. From 2010 to 2012, he served as Acting CEO of Nephros, Inc., during which period, the company obtained FDA clearance for its hemodiafiltration device, completed two strategic licensing transactions, and raised equity financing.